Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake
- PMID: 30850347
- PMCID: PMC6904789
- DOI: 10.1016/j.ijpddr.2019.02.005
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake
Abstract
In Brazil, cutaneous leishmaniasis is caused predominantly by L. (V.) braziliensis. The few therapeutic drugs available exhibit several limitations, mainly related to drug toxicity and reduced efficacy in some regions. Miltefosine (MF), the only oral drug available for leishmaniasis treatment, is not widely available and has not yet been approved for human use in Brazil. Our group previously reported the existence of differential susceptibility among L. (V.) braziliensis clinical isolates. In this work, we further characterized three of these isolates of L. (V.) braziliensis chosen because they exhibited the lowest and the highest MF half maximal inhibitory concentrations and were therefore considered less tolerant or more tolerant, respectively. Uptake of MF, and also of phosphocholine, were found to be significantly different in more tolerant parasites compared to the less sensitive isolate, which raised the hypothesis of differences in the MF transport complex Miltefosine Transporter (MT)-Ros3. Although some polymorphisms in those genes were found, they did not correlate with the drug susceptibility phenotype. Drug efflux and compartmentalization were similar in the isolates tested, and amphotericin B susceptibility was retained in MF tolerant parasites, suggesting that increased fitness was also not the basis of observed differences. Transcriptomic analysis revealed that Ros3 mRNA levels were upregulated in the sensitive strain compared to the tolerant ones. Increased mRNA abundance in more tolerant isolates was validated by quantitative PCR. Our results suggest that differential gene expression of the MT transporter complex is the basis of the differential susceptibility in these unselected, naturally occurring parasites.
Keywords: Isolates; Leishmania braziliensis; Miltefosine; RNAseq; Susceptibility; Uptake.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
Similar articles
-
Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major.ACS Infect Dis. 2021 Apr 9;7(4):849-858. doi: 10.1021/acsinfecdis.0c00857. Epub 2021 Mar 16. ACS Infect Dis. 2021. PMID: 33724800 Free PMC article.
-
Susceptibility to Miltefosine in Brazilian Clinical Isolates of Leishmania (Viannia) braziliensis.Am J Trop Med Hyg. 2017 Mar;96(3):656-659. doi: 10.4269/ajtmh.16-0811. Epub 2017 Apr 6. Am J Trop Med Hyg. 2017. PMID: 28070006 Free PMC article.
-
Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.Biomed Pharmacother. 2018 Dec;108:1170-1180. doi: 10.1016/j.biopha.2018.09.149. Epub 2018 Oct 2. Biomed Pharmacother. 2018. PMID: 30372818
-
Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications.Acta Trop. 2017 Dec;176:150-161. doi: 10.1016/j.actatropica.2017.07.026. Epub 2017 Jul 24. Acta Trop. 2017. PMID: 28751163 Review.
-
American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.Trop Med Int Health. 2019 Apr;24(4):380-391. doi: 10.1111/tmi.13210. Epub 2019 Feb 19. Trop Med Int Health. 2019. PMID: 30681239 Review.
Cited by
-
Advances in Understanding Leishmania Pathobiology: What Does RNA-Seq Tell Us?Front Cell Dev Biol. 2021 Sep 1;9:702240. doi: 10.3389/fcell.2021.702240. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34540827 Free PMC article. Review.
-
Repositioning of Tamoxifen in Surface-Modified Nanocapsules as a Promising Oral Treatment for Visceral Leishmaniasis.Pharmaceutics. 2021 Jul 10;13(7):1061. doi: 10.3390/pharmaceutics13071061. Pharmaceutics. 2021. PMID: 34371752 Free PMC article.
-
Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major.ACS Infect Dis. 2021 Apr 9;7(4):849-858. doi: 10.1021/acsinfecdis.0c00857. Epub 2021 Mar 16. ACS Infect Dis. 2021. PMID: 33724800 Free PMC article.
References
-
- Andrews S. 2010. FASTQC. A quality control tool for high throughput sequence data.http://www.bioinformatics.babraham.ac.uk/projects/fastqc Available at.
-
- Aslett M., Aurrecoechea C., Berriman M., Brestelli J., Brunk B.P., Carrington M., Depledge D.P., Fischer S., Gajria B., Gao X., Gardner M.J., Gingle A., Grant G., Harb O.S., Heiges M., Hertz-Fowler C., Houston R., Innamorato F., Iodice J., Kissinger J.C., Kraemer E., Li W., Logan F.J., Miller J.A., Mitra S., Myler P.J., Nayak V., Pennington C., Phan I., Pinney D.F., Ramasamy G., Rogers M.B., Roos D.S., Ross C., Sivam D., Smith D.F., Srinivasamoorthy G., Stoeckert C.J., Jr., Subramanian S., Thibodeau R., Tivey A., Treatman C., Velarde G., Wang H. TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res. 2010;38:D457–D462. - PMC - PubMed
-
- Banuls A.L., Hide M., Prugnolle F. Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans. Adv. Parasitol. 2007;64:1–109. - PubMed
-
- Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B. 1995;57:289–300.
-
- Bhandari V., Kulshrestha A., Deep D.K., Stark O., Prajapati V.K., Ramesh V., Sundar S., Schonian G., Dujardin J.C., Salotra P. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Neglected Trop. Dis. 2012;6 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
